| abstract |
1. The combination of the peptides Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 and Pyr-Leu- Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu- Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 or their salts or hydrates. ! 2. The combination according to claim 1, where the peptides are contained in combination in an amount of from 30 wt.% To 70 wt.% To 70 wt.% To 30 wt.%. ! 3. The combination according to claim 1 for use in medicine. ! 4. The use of the peptide Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2, or a combination according to claim 1, or 2, or 3 to obtain a pharmaceutical composition for the treatment and / or prophylaxis of a malignant tumor, autoimmune diseases, fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and blood vessel diseases and metabolic diseases. ! 5. The use of the peptide according to claim 4, where the infectious disease is selected from Mycobacterium tuberculosis infection and infectious diseases caused by Mycobacterium tuberculosis infection selected from infectious diseases of the lung, central nervous system, lymphatic system, circulatory system, genitourinary system, bones, joints and skin . ! 6. The use of the peptide Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 to obtain the composition for oral administration the introduction of newborns, toddlers and / or preschool children. ! 7. The use of the peptide Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 to obtain a lyophilized composition or buffer liquid composition. ! 8. A pharmaceutical composition comprising a combination according to claim 1 together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotector, excipient and / or diluent. ! 9. The pharmaceutical composition of claim 8 in the form of l |